Acceptance of the Protocol Amending the TRIPS Agreement

Slides:



Advertisements
Similar presentations
TRIPs and Public Health: The Unresolved Debate Tenu Avafia tralac
Advertisements

1 WTO and medicines: from Doha to Cancún Germán Velásquez Essential Drugs and Medicines Policy World Health Organization Geneva, October 2003.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
Using FTA Side Letters and Congressional Letters to Authorize Waiver of Data Exclusivity and Linkage Professor Brook K. Baker Northeastern U. School of.
J.P. Singh Georgetown University Communication, Culture, & Technology Program TRIPS: Negotiating Intellectual Property in the World Trading System J.
RECOMMENDATIONS BY INTELLECTUAL PROPERTY LAWYERS ON LEGAL REFORM MOSES NKOMO LL.B, MIP.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
Ato2461 INTELLECTUAL PROPERTY AND DEVELOPMENT Presentation by Adrian Otten Director, Intellectual Property Division, WTO Secretariat Panel Discussion 7.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Challenges and Opportunities to Utilize TRIPS Flexibilities in Current Ukrainian Legislation: Potential Impact of IP Provisions in the Proposed EU FTA.
Greedy Sleazy Patent Owners vs. Poor Sick People International Patent Protection and Access to Drugs in the Third World Liz Durham November 4, 2003.
Intellectual Property Rights, Services and Trade Facilitation CARSTEN FINK African/LDCs Ambassadors Seminar on Post-Hong Kong Assessment of the Doha Round,
RATIFICATION OF FINAL ACTS AND DECISIONS OF THE 1999 BEIJING CONGRESS – UNIVERSAL POSTAL UNION.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
1 ICC and AIPLA Paris, September 13, 2002 Felix Addor Chief Legal Officer and Deputy Director General Swiss Federal Institute of Intellectual Property.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
The TRIPs Amendment: Developments and implications Tralac/ Comomonwealth post Hong Kong Conference 10 April 2006 Tenu Avafia UNDP.
1 Intellectual Property Rights in Medicines Procurement Patrick Osewe Senior HIV/AIDS Specialist World Bank.
A very short introduction to patents & access to medicines.
Medicines & Related Substances Amendment Bill: Protecting the Nation’s Health “The State must take reasonable legislative and other measures, within its.
Patent Related Flexibilities in the Pharmaceutical Field
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Patents, TRIPS, Flexibilities & Access to Medicines –Legal Perspective Lesotho Civil Society Consultation Meeting 12 August 2014.
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Trade-related policies and access to medicines ICTSD Consultation on trade policy coherence and access to medicines Geneva November 7 th 2006,
LESOTHO VALIDATION WORKSHOP 25 NOVEMBER 2014 CAILIN MORRISON RECAP – THE INTERNATIONAL CONTEXT: THE WTO, PATENTS, TRIPS FLEXIBILITIES & ACCESS TO MEDICINES.
Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.
WHO Perspective on Medicine Patents and FTAs Asian Regional Workshop on FTAs August, 2005, Kuala Lumpur, Malaysia Dr Zafar Mirza Regional Adviser,
1 CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur Session 10.
Zimbabwe CSOs TRIPS and Access to medicines Aulline Mabika-Chapisa.
Ten Years of the Doha Declaration: The State of Implementation Geneva 14 November
Page 1 Implementation of the WTO Decision on TRIPS and Public Health Government of Canada August 2004.
The Doha Declaration and the Protocol amending the TRIPS Agreement Islamabad, 28 November 2007 Octavio Espinosa WIPO.
UNCTAD/CD-TFT 1 Exclusive Rights and Public Access – Flexibilities in International Agreements and Development Objectives The Public Health Example 21.
O VERVIEW OF P UBLIC H EALTH -R ELATED TRIPS F LEXIBILITIES Sisule F. Musungu, IQsensato (
Intellectual Property Rights and Pharmaceuticals (Case study- Novartis’s claim in India) Background note prepared for PHM Vic Internet Workshop.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Membership (I) Membership (currently 160 Members): who can be a Member? -States; -separate customs territory (Macao, Hong Kong, Chinese Taipei) -European.
Protection of IPRs in Accession to WTO. Accession negotiations Multilateral (rules) Bilateral (individual members’ demands)
DOMESTICATION OF TRIPS FLEXIBILITIES IN NATIONAL IP LEGISLATION FOR STRENGTHENING ACCESS TO MEDICINES IN ZAMBIA PROPOSED PATENT BILL AND ITS RELEVANCY.
Data Protection in compliance with Article 39 of the TRIPS Agreement Draft Amendment to the Drugs Act 1976 Humaira Mufti WIPO National Seminar on Flexibilities.
International Trade Regulations: the Law of the WTO Professor Mohammad F. A. Nsour Class 3 1.
IMPACT OF THE DOHA DECLARATION November 14, 2011 Carlos M. Correa.
WTO and the TRIPS Agreement Wolf R. MEIER-EWERT WTO Secretariat A Business-oriented overview of Intellectual Property for Law Students WIPO, Geneva 20.
A presentation by Moses Nkomo Intellectual Property Attorney and Consultant National Workshop on TRIPS and access to medicines in Zimbabwe Holiday Inn,
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
Intellectual Property Negotiations Between the United States and Colombia, Peru and Equator for a Free Trade Agreement, Relating to Medicine James Love.
Overview: The South African IP Policy Review 13 September 2012 MacDonald Netshitenzhe: Chief Director- Policy and Legislation.
Access v. Patents: We Still Can’t Get Along Srividhya Ragavan University of Oklahoma Law Center.
1 Special mechanism for the importation of pharmaceutical products under the TRIPS Agreement Carlos M. Correa.
International Intellectual Property Prof. Manheim Spring, 2007 Patent Compulsory Licensing Copyright © 2007.
TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).
Dialogue on Competition Policy and Intellectual Property *
Overview of presentation
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
WTO and medicines: from Doha to Cancún
Department of Trade and Industry
Intellectual Property Protection and Access to Medicines
Package of agreements annexed to the WTO Agreement
PATENTS, TRIPS, FLEXIBILITIES & ACCESS TO MEDICINES
WIPO NATIONAL SEMINAR ON INTELLECTUAL PROPERTY RIGHTS AND THE PROTECTION OF PHARMACEUTICAL PRODUCTS Damascus, April 25 and 26, 2005 Current issues on Intellectual.
Béchir N’Daw, UNAIDS Secretariat
Amendment procedure Amendment proposal by one Member or a specialised Council; decision adopted by the Ministerial Conference or the General Council by.
Trade-related policies and access to medicines
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
Intellectual Property Rights in Medicines Procurement
Presentation transcript:

Acceptance of the Protocol Amending the TRIPS Agreement South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015

BACKGROUND The Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the WTO. TRIPS is the most important and comprehensive agreement dealing with IP rights. TRIPS agreement introduced intellectual property law into the international trading system for the first time. South Africa is member of TRIPS because of the Single Undertaking Rule in the WTO.

KEY OBJECTIVES OF THE FLEXIBILITY Addresses the impact of the TRIPS Agreement on access to drugs, local manufacturing capacity and the development of new drugs. Africa Group proposal to ensure that the TRIPS Agreement does not undermine the legitimate right of WTO Members to formulate their own public health policies. Emphasis on access to medicines and R&D for prevention and treatment of diseases predominantly affecting people in developing and LDCs. Developing countries cannot afford to pay the prices asked by the developed countries’ pharmaceutical companies for the drugs which these companies have developed and produced, which often include the only effective treatment for national health emergencies such as the HIV/Aids pandemic. Parallel imports are imports of a patented or trademarked product from a country where it is already marketed. For example, if 100 units of Bayer's Malaria drugs costs R 200 in South Africa, but in India Bayer sells the same drug for R 50 (owing to local generic competition). Mozambique can import the product from India without Bayer's consent. Compulsory licensing is when a government allows someone else (Generic Company) to produce the patented product (drug) or process without the consent of the patent owner. This could happen if there is a national health emergency and the patent owner of the only effective treatment for pendemics such as the HIV/Aids or Ebola sells the drug at astronomically high prices which the Government cannot afford to pay.

KEY OBJECTIVES OF THE FLEXIBILITY Initial resistance by developed countries (US, Japan, Switzerland, Australia and Canada) stressing the importance of intellectual property protection for R&D and that IP contributes to public health. Despite initial resistance Doha Declaration was adopted by consensus. Recognizes that the high prices of medicines caused by patent protection are part of the grave problems that afflict developing countries and LDCs and is a "concern" that needs to be addressed. Developing countries cannot afford to pay the prices asked by the developed countries’ pharmaceutical companies for the drugs which these companies have developed and produced, which often include the only effective treatment for national health emergencies such as the HIV/Aids pandemic. Parallel imports are imports of a patented or trademarked product from a country where it is already marketed. For example, if 100 units of Bayer's Malaria drugs costs R 200 in South Africa, but in India Bayer sells the same drug for R 50 (owing to local generic competition). Mozambique can import the product from India without Bayer's consent. Compulsory licensing is when a government allows someone else (Generic Company) to produce the patented product (drug) or process without the consent of the patent owner. This could happen if there is a national health emergency and the patent owner of the only effective treatment for pendemics such as the HIV/Aids or Ebola sells the drug at astronomically high prices which the Government cannot afford to pay.

2001 DECLARATION November 2001 Doha Meeting, developing countries demanded a reassessment of TRIPS Purpose: (1) address high prices of medicines charged by developed countries’ pharmaceutical companies. (2) ensure that developing countries could either produce affordable generic drugs (compulsory licensing) or buy them from elsewhere (parallel imports) at reasonable prices, especially in a national health emergency situation. Developing countries cannot afford to pay the prices asked by the developed countries’ pharmaceutical companies for the drugs which these companies have developed and produced, which often include the only effective treatment for national health emergencies such as the HIV/Aids pandemic. Parallel imports are imports of a patented or trademarked product from a country where it is already marketed. For example, if 100 units of Bayer's Malaria drugs costs R 200 in South Africa, but in India Bayer sells the same drug for R 50 (owing to local generic competition). Mozambique can import the product from India without Bayer's consent. Compulsory licensing is when a government allows someone else (Generic Company) to produce the patented product (drug) or process without the consent of the patent owner. This could happen if there is a national health emergency and the patent owner of the only effective treatment for pendemics such as the HIV/Aids or Ebola sells the drug at astronomically high prices which the Government cannot afford to pay.

DECLARATION CONTENT Recognition of the gravity of the public health problems...,especially those resulting from HIV/AIDS, tuberculosis, malaria and other epidemics Recognition that intellectual property protection is important for the development of new medicines and recognise concerns about its effects on prices Agreement that the TRIPS Agreement does not and should not prevent Members from taking measures to protect public health. Reaffirmation that TRIPS can and should be interpreted and implemented in a manner supportive of Members’ right to protect public health and, in particular, to promote access to medicines for all.

DECLARATION CONTENT cont.. Clarifies that “public health crises” can represent “a national emergency or other circumstances of extreme urgency”, and that an “emergency” may be either a short-term problem, or a long-lasting situation. Places the burden on a complaining Member to prove that an emergency or urgency does not exist. It is implicit within the Declaration that differentiation in patent rules may be necessary to protect public health - recognition that public health-related patents may be treated differently from other patents. Makes it easier for developing countries to adopt measures necessary to ensure access to health care without the fear of being dragged into a legal battle.

DECLARATION CONTENT cont.. Gives Members more flexibility: in utilising parallel import mechanism and in the granting of compulsory licences. to determine through their own national legislations the grounds upon which such licences are to be granted, to decide what constitutes a national public health emergency. to cover any “public health problem” – not limited to specific diseases Though access to medicines was preoccupation -covers any product, method or technology for health care. Applies to pharmaceutical products, processes and uses, surgical, therapeutic and diagnostic methods, diagnostic kits as well as medical equipment.

DECEMBER 2005 DECISION 2003 decision which gives effect to the 2001 Declaration and calls for the amendment of the TRIPS Agreement 2005 Decision finds its basis from paragraph 11 of August 2003 Decision which instructed TRIPS Council to initiate work on amendment by end 2003 with a view to its adoption within 6 months Adopts Protocol Amending the TRIPS Agreement and submits it to Members for acceptance Protocol open for acceptance until 1/12/2007 Period extended a number of times due to low number of instruments of acceptance deposited with the WTO Secretariat Period extended a number of times due to low number of instruments of acceptance deposited with the WTO Secretariat which is why its important for us to ratify.

DECEMBER 2005 DECISION cont… Latest deadline expires 31/12/2015 but will be extended at MC 10 Takes effect upon acceptance by two thirds of membership Period extended a number of times due to low number of instruments of acceptance deposited with the WTO Secretariat which is why its important for us to ratify.

CONSTITUTION Section 27 (1): Everyone has the right to have access to (a) health care services, including reproductive health care; 27 (2): The state must take reasonable legislative and other measures, within its available resources, to achieve the progressive realisation of each of these rights. Section 27 therefore places a positive obligation on the State to accept the 2005 Protocol Acceptance by SA will contribute to the current number of acceptances in order to reach the two thirds majority threshold for the Protocol to come into force (Article X iii) Article X(iii) WTO Agreement Amendments to provisions of this Agreement, or of the Multilateral Trade Agreements in Annexes 1A and 1C, other than those listed in paragraphs 2 and 6, of a nature that would alter the rights and obligations of the Members, shall take effect for the Members that have accepted them upon acceptance by two thirds of the Members and thereafter for each other Member upon acceptance by it. The Ministerial Conference may decide by a three-fourths majority of the Members that any amendment made effective under this paragraph is of such a nature that any Member which has not accepted it within a period specified by the Ministerial Conference in each case shall be free to withdraw from the WTO or to remain a Member with the consent of the Ministerial Conference.

CONSTITUTION cont…. WTO Agreement falls under section 231(2) Section 231(2): An international agreement binds the Republic only after it has been approved by resolution in both the National Assembly and the National Council of Provinces, unless it is an agreement referred to in subsection (3). Any amendment to an agreement referred to above will also have to follow the same process Legal opinions from DIRCO and DoJ confirm this position Instrument of Acceptance to be deposited with the WTO to confirm our acceptance of the amendment

BENEFITS Government will be able to fully implement flexibilities provided by such amendments Full and effective implementation of flexibilities will enable Government to provide access to cheaper and better health care Work on the IP policy review already underway to come up with proposals on how to effectively take advantage and implement these flexibilities Policy and Legislation Unit deals with IP policy review